Abstract:Abstract Background Current efforts to expand the pool of available markers that can be analyzed in clinical settings is hampered by limited volumes of biomaterial-rich fluids and low concentrations of certain analytes, coupled with poor sensitivity of existing detection techniques. Although progress has been made using advanced sample preparation or assay techniques such as miRNeasy or ELISA for genomic and protein assays, respectively, little research has focused on adapting new optical methods as detection modes in the clinic. Amplified Sciences has developed an enzymatic activity assay platform using SERS detection to improve diagnostic sensitivities in multiple disease indications. Along with the experts at Wasatch Photonics, research focused on adaptation of this assay platform has enabled investigation of multiple markers of disease that had previously been undervalued or overlooked, as well as stacking of multiple markers in precious, low-volume samples. Methods Building upon previously published data using gastricsin as a marker to identify benign, non-mucinous pancreatic cysts, Amplified Sciences has added several SERS laser wavelengths, and different sample preparation methods to the existing platform. To examine the sensitivities of laser and dye combinations, solutions representative of assay samples containing rhodamine-dimer dye-labeled peptide were tested using Wasatch Photonics Raman spectrometers at 532, 638, 785, and 830 nm laser wavelengths. Samples at different pH were analyzed after addition of colloidal Au or Ag nanoparticles to determine the impacts of sample preparation on SERS spectral features. After drying in a desiccator overnight, the samples were reanalyzed to assess the stability of the SERS signals. As a pertinent application of this technology, an activity assay was developed for the known COVID protease 3ClPro. Release of rhodamine dimer dye as a result of 3ClPro cleavage of the substrate was quantified using SERS. The data were analyzed using Bruker OPUS Software package, and plotted using Graphpad Prism 9. Results Each laser, buffer, and metal used for SERS provided a unique spectral signature, suggesting that different transitions are available and potentially tunable depending on the application under investigation. Sensitivity was, as expected, best with the 532 nm SERS system purportedly due to enhancement factors, and the resonance impacts of rhodamine dyes at 532 nm. It was found that the Limit of Detection of Rhodamine-dimer dye was 100-fold lower with SERS compared to fluorescence, even after a 3-fold dilution with colloidal Ag. However, the remaining lasers could be more finely tuned, and, thus, provide alternate spectral properties, and different sensitivities which has implications when new dye classes are introduced into the platform. Furthermore, when SERS was applied to the 3ClPro assay, it was determined that activity could be detected below the dimerization concentration of 3ClPro, described in the literature as ∼25 nM. Also, a monomeric version of 3ClPro that is expected to have no reactivity with the substrate was found to display activity above background at concentrations as low as 1 μM. Conclusion SERS is an appropriate method for measuring activity in clinically relevant markers of disease, with tunable characteristics based upon the dye composition and the spectrometer in use.

Amplification-Free Sers Analysis Of Dna Mutation In Cancer Cells With Single-Base Sensitivity

Single-molecule detection of cancer mutations using a novel PCR-LDR-qPCR assay

Synergistic enhanced rolling circle amplification based on mutS and radical polymerization for single-point mutation DNA detection

Highly-selective detection of EGFR mutation gene in lung cancer based on surface enhanced Raman spectroscopy and asymmetric PCR

Ultrasensitive detection of cancer-associated nucleic acids and mutations by primer exchange reaction-based signal amplification and flow cytometry

DNA-encoded Plasmonic Bubbles Aggregating Dual-Microrna SERS Signals for Cancer Diagnosis

SERS Nanoprobes in Biologically Raman Silent Region for Tumor Cell Imaging and in Vivo Tumor Spectral Detection in Mice

Combined SERS Microfluidic Chip with Gold Nanocone Array for Effective Early Lung Cancer Prognosis in Mice Model

Development of a Single Quantum Dot-Mediated FRET Nanosensor for Sensitive Detection of Single-Nucleotide Polymorphism in Cancer Cells

A pump-free and high-throughput microfluidic chip for highly sensitive SERS assay of gastric cancer-related circulating tumor DNA via a cascade signal amplification strategy

Fe-Au Nanoparticle-Coupling for Ultrasensitive Detections of Circulating Tumor DNA

Discrimination of Genetic Biomarkers of Disease through Machine-Learning-Based Hypothesis Testing of Direct SERS Spectra of DNA and RNA

SERS-based methods for the detection of genomic biomarkers of cancer

B-358 Application of Surface-Enhanced Raman Spectroscopy to Improve Sensitivity of Clinical Assays

Dna Terminal Structure-Mediated Enzymatic Reaction For Ultra-Sensitive Discrimination Of Single Nucleotide Variations In Circulating Cell-Free Dna

Recent advances in surface-enhanced Raman spectroscopy for the detection of tumor markers

Surface enhanced Raman spectroscopy for tumor nucleic acid: Towards cancer diagnosis and precision medicine

Label-free amplified fluorescence detection of DNA biomarkers based on KFP polymerase-driven double strand displacement reactions and magnetic nanoprobes

Electroporation-Assisted Surface-Enhanced Raman Detection for Long-Term, Label-Free, and Noninvasive Molecular Profiling of Live Single Cells

Overhang Molecular Beacons Encapsulated in Tethered Cationic Lipoplex Nanoparticles for Detection of Single-Point Mutation in Extracellular Vesicle-Associated RNAs.

DNA Self-Assembled Au Nanoparticle Clusters on Silver Nanorod Arrays for High-Sensitive and Multiplex Detection of Cancer-Related Biomarkers.